| Matthew Wood, DO | |
|
3401 W Gore Blvd, Attn Em Residency Coordinator, Lawton, OK 73505-6332 | |
| (580) 585-5548 | |
| Not Available |
| Full Name | Matthew Wood |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 3401 W Gore Blvd, Lawton, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972918720 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 5841 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ssm Health St Anthony Hospital - Oklahoma City | Oklahoma city, OK | Hospital |
| Ssm Health St Anthony Hospital - Shawnee | Shawnee, OK | Hospital |
| Purcell Municipal Hospital | Purcell, OK | Hospital |
| Oklahoma Heart Hospital South, Llc | Oklahoma city, OK | Hospital |
| Alliancehealth Midwest | Midwest city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Physicians Of Mid-america Pc | 2062638661 | 80 |
News Archive
The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.
Prostasin, a relatively unknown protease enzyme expressed in most epithelial cells, may play a role in the genesis of colorectal cancer. Researchers writing in the open access journal BMC Cancer have associated a reduction in the expression of inhibitors of the enzyme with malignant cellular behavior.
› Verified 7 days ago
| Entity Name | Carnegie Tri-county Municipal Hospital Management Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275657017 PECOS PAC ID: 6800835935 Enrollment ID: O20050429000480 |
News Archive
The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.
Prostasin, a relatively unknown protease enzyme expressed in most epithelial cells, may play a role in the genesis of colorectal cancer. Researchers writing in the open access journal BMC Cancer have associated a reduction in the expression of inhibitors of the enzyme with malignant cellular behavior.
› Verified 7 days ago
| Entity Name | Lawton Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518003656 PECOS PAC ID: 9537265392 Enrollment ID: O20070511000067 |
News Archive
The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.
Prostasin, a relatively unknown protease enzyme expressed in most epithelial cells, may play a role in the genesis of colorectal cancer. Researchers writing in the open access journal BMC Cancer have associated a reduction in the expression of inhibitors of the enzyme with malignant cellular behavior.
› Verified 7 days ago
| Entity Name | Emergency Services Of Oklahoma Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215249891 PECOS PAC ID: 8123209012 Enrollment ID: O20110225000085 |
News Archive
The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.
Prostasin, a relatively unknown protease enzyme expressed in most epithelial cells, may play a role in the genesis of colorectal cancer. Researchers writing in the open access journal BMC Cancer have associated a reduction in the expression of inhibitors of the enzyme with malignant cellular behavior.
› Verified 7 days ago
| Entity Name | South Central Emergency Services, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558663724 PECOS PAC ID: 8224212949 Enrollment ID: O20110405000201 |
News Archive
The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.
Prostasin, a relatively unknown protease enzyme expressed in most epithelial cells, may play a role in the genesis of colorectal cancer. Researchers writing in the open access journal BMC Cancer have associated a reduction in the expression of inhibitors of the enzyme with malignant cellular behavior.
› Verified 7 days ago
| Entity Name | Oklahoma Emergency Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114239795 PECOS PAC ID: 3678757010 Enrollment ID: O20110411000211 |
News Archive
The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.
Prostasin, a relatively unknown protease enzyme expressed in most epithelial cells, may play a role in the genesis of colorectal cancer. Researchers writing in the open access journal BMC Cancer have associated a reduction in the expression of inhibitors of the enzyme with malignant cellular behavior.
› Verified 7 days ago
| Entity Name | Oklahoma Emergency Physician Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891039764 PECOS PAC ID: 0345493649 Enrollment ID: O20130118000115 |
News Archive
The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.
Prostasin, a relatively unknown protease enzyme expressed in most epithelial cells, may play a role in the genesis of colorectal cancer. Researchers writing in the open access journal BMC Cancer have associated a reduction in the expression of inhibitors of the enzyme with malignant cellular behavior.
› Verified 7 days ago
| Entity Name | Emergency Physicians Of Mid-america Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063825297 PECOS PAC ID: 2062638661 Enrollment ID: O20140716001692 |
News Archive
The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.
Prostasin, a relatively unknown protease enzyme expressed in most epithelial cells, may play a role in the genesis of colorectal cancer. Researchers writing in the open access journal BMC Cancer have associated a reduction in the expression of inhibitors of the enzyme with malignant cellular behavior.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Wood, DO 3401 W Gore Blvd, Attn Em Residency Coordinator, Lawton, OK 73505-6332 Ph: (580) 585-5548 | Matthew Wood, DO 3401 W Gore Blvd, Attn Em Residency Coordinator, Lawton, OK 73505-6332 Ph: (580) 585-5548 |
News Archive
The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
The link between deficits of omega-3 poly-unsaturated fatty acids and the onset of depressive disorders is not new in the medical field. However, what has not been known until now is the brain mechanism by which diet can condition mental health to a certain extent.
Prostasin, a relatively unknown protease enzyme expressed in most epithelial cells, may play a role in the genesis of colorectal cancer. Researchers writing in the open access journal BMC Cancer have associated a reduction in the expression of inhibitors of the enzyme with malignant cellular behavior.
› Verified 7 days ago
Daniel Dorton, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3401 W Gore Blvd # W, Lawton, OK 73505 Phone: 580-699-4322 | |
Dr. Kirk M. Smith, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4909 Se Mills Ave, Lawton, OK 73501 Phone: 580-890-0545 | |
Dr. Justin M Magalassi, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3401 W Gore Blvd, Lawton, OK 73505 Phone: 918-519-2011 | |
Dr. Manuel Delarosa, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Nw 67th St, Suite E, Lawton, OK 73505 Phone: 580-536-9400 | |
Ryan Dale Ford, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4510 Sw Wendy Dr, Lawton, OK 73505 Phone: 580-355-8620 | |
Dr. Andrew Burnette, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3401 W Gore Blvd, Lawton, OK 73505 Phone: 580-585-5545 | |
David W. Behm, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5602 Sw Lee Blvd, Er Dept, Lawton, OK 73505 Phone: 580-531-4700 Fax: 405-749-4561 |